Biotech Stocks Touched New Highs: Cambrex Corporation. (NYSE:CBM), Biogen Idec Inc. (NASDAQ:BIIB), Coherus Biosciences (NASDAQ:CHRS), ImmuCell (NASDAQ:ICCC), Esperion Therapeutics (NASDAQ:ESPR)

Cambrex Corporation. (NYSE:CBM) reported Fourth quarter 2014 sales increased 25% to $128.8 million from $103.0 million in the same period last year. Full year 2014 sales increased 18%, and 19% excluding the impact of foreign currency. On Friday shares of Cambrex Corporation. (NYSE:CBM) closed at $30.01. Company’s sales growth for last 5 years was 5.00% and EPS growth for next 5 years is recorded as 21.00%.

On 29 January, Biotech company, Biogen Idec (NASDAQ:BIIB), reported fourth quarter 2014 earnings per share of $4.08 (including the impact of stock-based compensation expense), way above the Zacks Consensus Estimate of $3.74 and the year-ago earnings of $2.33 per share.Biogen Idec Inc. (NASDAQ:BIIB) in last trading activity increased 0.05% to close at $402.00. Company weekly performance is 3.30% while its quarterly performance stands at 25.80%. Biogen Idec Inc. (NASDAQ:BIIB) is -0.10% away from its 52 week high.

Coherus BioSciences, Inc. (NASDAQ:CHRS), announced that it will participate in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11 at 1:50 pm ET in New York City. On last trading day Coherus Biosciences, Inc. (NASDAQ:CHRS) increased 17.51% to close at $28.66. Its volatility for the week is 11.18% while volatility for the month is 9.98%. CHRS’s EPS growth for past 5 years was -44.33%. Coherus Biosciences, Inc. (NASDAQ:CHRS) monthly performance is 44.82%.

ImmuCell Corporation (NASDAQ: ICCC), will report 2014 full year and fourth quarter financial results after the market closes on Wednesday, February 11, 2015. ImmuCell Corp. (NASDAQ:ICCC) has 8.60% insider ownership while its institutional ownership stands at 8.50%. In last trading activity company’s stock closed at $6.55.

On 2 February, Esperion Therapeutics (NASDAQ:ESPR) announced that the FDA has removed the peroxisome proliferator-activated receptor partial clinical hold on ETC-1002. On last trading day Esperion Therapeutics, Inc. (NASDAQ:ESPR) increased 1.47% to close at $59.39. Its volatility for the week is 9.47% while volatility for the month is 8.68%. ESPR’s EPS growth for past 5 years was -29.50%. Esperion Therapeutics, Inc. (NASDAQ:ESPR) monthly performance is 26.17%.

Leave a Reply

Your email address will not be published. Required fields are marked *